Limitations of the use of single base changes in the p53 gene to detect minimal residual disease of breast cancer.
OBJECTIVE
Peripheral blood progenitor cell (PBPC) transplantation is frequently used in the treatment of malignant diseases, but contamination of the graft by tumour cells is a real concern and may lead to disease relapse. The feasibility of applying heterogeneous single base genetic changes as tumour specific markers to detect minimal residual disease in PBPC harvests was studied, using the p53 gene and breast cancer as models.


METHODS
Tumour tissues from 51 patients with cellular aliquots from PBPC harvests available were studied. Thirty eight patients had metastatic disease or were at high risk of metastasis, and 13 had high risk stage II/III disease with four or more involved axillary lymph nodes. Tumour DNA was screened for p53 mutations in exons 5 to 9, using denaturing gradient gel electrophoresis, followed by sequencing. Based on sequence information, allele specific primers were designed for each mutation and the non-radioisotopic, amplification refractory mutation system (ARMS) was used to screen DNA from PBPC harvests for minimal residual disease. Attempts were made to optimise each system, based on parameters determined using the T47D breast cancer cell line with a confirmed point mutation in codon 194.


RESULTS
Twelve different somatic mutations were found, two of which could not be sequenced. The remainder were point mutations. Only five of the 10 ARMS systems were successfully optimised, and minimal residual disease detection sensitivities ranged from one copy of tumour DNA in 10(2) to 10(3) copies of wild-type DNA. Using ARMS, three of five patients and eight of 12 of their PBPC harvests showed minimal residual disease.


CONCLUSIONS
These results suggest that the use of single base genetic changes in minimal residual disease detection is relatively insensitive and is limited to a small number of patients and to certain mutations. In addition, it is labourious and therefore unlikely to play an important role in clinical practice.
Dang
R K B
RK
Department of Haematology, Western General Hospital, Edinburgh EH4 2XU, UK. rdang@doctors.org.uk
Anthony
R S
RS
Craig
J I O
JI
Leonard
R C F
RC
Parker
A C
AC
D001943:Breast Neoplasms / Q000473:pathology* / Q000628:therapy; D004252:DNA Mutational Analysis; D004273:DNA, Neoplasm / Q000235:genetics; D005240:Feasibility Studies; D005260:Female; D016158:Genes, p53 / Q000235:genetics*; D005819:Genetic Markers; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells; D006801:Humans; D009154:Mutation; D018365:Neoplasm, Residual / Q000175:diagnosis*; D009360:Neoplastic Cells, Circulating; D017354:Point Mutation
D004273:DNA, Neoplasm; D005819:Genetic Markers